title: CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer.
abstract: Between November 1984 and January 1987, 19 patients with epithelial ovarian cancer were monitored with CA-125 values during second-line therapy. There was a statistically significant association between clinical response to therapy and CA-125 trend when trend was defined as a greater than or equal to 26% change in CA-125 from baseline value to last value prior to demonstration of clinical response (p = 0.0002). In 8 of 11 patients (73%), increasing CA-125 values were predictive of clinical progression during second-line therapy. In six of seven patients (86%), decreasing values predicted clinical regression. Three patients began second-line therapy with baseline values less than 35 U/ml. Two of these progressed during second-line therapy while the third progressed in follow-up. Two of four complete clinical responders completed second-line therapy with values less than 35 U/ml. Both progressed in follow-up with increasing CA-125 values. In this analysis, a 26% change in CA-125 values was a useful predictor of clinical response in patients receiving second-line therapy for epithelial ovarian cancer. Patients undergoing second-line chemotherapy with values less than 35 U/ml may still benefit from CA-125 monitoring.
authors.affiliation: Department of Obstetrics and Gynecology, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27103.
authors.forename: L W
authors.initials: LW
authors.lastname: Ng
authors.forename: H D
authors.initials: HD
authors.lastname: Homesley
authors.forename: R J
authors.initials: RJ
authors.lastname: Barrett
authors.forename: C E
authors.initials: CE
authors.lastname: Welander
authors.forename: L D
authors.initials: LD
authors.lastname: Case
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D004715:Endometriosis / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011336:Probability; D012189:Retrospective Studies
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents